HANDOK Inc. (002390.KS)
KRW 12270.0
(-2.54%)
KRW 12270.0
(-2.54%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 12.57 Billion KRW | -35.39% |
| 2022 | 19.46 Billion KRW | 10.38% |
| 2021 | 17.63 Billion KRW | -63.22% |
| 2020 | 47.95 Billion KRW | -16.46% |
| 2019 | 57.39 Billion KRW | 266.73% |
| 2018 | 15.65 Billion KRW | 936.69% |
| 2017 | -1.87 Billion KRW | -151.39% |
| 2016 | 3.64 Billion KRW | -41.49% |
| 2015 | 6.22 Billion KRW | -39.69% |
| 2014 | 10.31 Billion KRW | 38.23% |
| 2013 | 7.46 Billion KRW | -13.21% |
| 2012 | 8.59 Billion KRW | -59.47% |
| 2011 | 21.21 Billion KRW | -20.88% |
| 2010 | 26.8 Billion KRW | 38.16% |
| 2009 | 19.4 Billion KRW | -22.57% |
| 2008 | 25.06 Billion KRW | -18.9% |
| 2007 | 30.9 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -2.35 Billion KRW | -226.25% |
| 2024 Q1 | 4.64 Billion KRW | 309.6% |
| 2024 Q2 | 1.86 Billion KRW | -59.85% |
| 2023 Q2 | 4.74 Billion KRW | 95.32% |
| 2023 Q1 | 2.42 Billion KRW | -90.16% |
| 2023 FY | 12.57 Billion KRW | -35.39% |
| 2023 Q3 | 4.85 Billion KRW | 2.39% |
| 2023 Q4 | -2.21 Billion KRW | -145.6% |
| 2022 Q3 | 9.3 Billion KRW | 305.99% |
| 2022 Q2 | -4.51 Billion KRW | -175.48% |
| 2022 FY | 19.46 Billion KRW | 10.38% |
| 2022 Q4 | 24.67 Billion KRW | 165.23% |
| 2022 Q1 | 5.98 Billion KRW | 94.09% |
| 2021 Q3 | 8.07 Billion KRW | 19.13% |
| 2021 Q1 | 6.78 Billion KRW | 76.28% |
| 2021 Q2 | 6.77 Billion KRW | -0.18% |
| 2021 Q4 | 3.08 Billion KRW | -61.81% |
| 2021 FY | 17.63 Billion KRW | -63.22% |
| 2020 FY | 47.95 Billion KRW | -16.46% |
| 2020 Q1 | 7.03 Billion KRW | -7.86% |
| 2020 Q2 | 7.21 Billion KRW | 2.47% |
| 2020 Q4 | 3.85 Billion KRW | -62.53% |
| 2020 Q3 | 10.27 Billion KRW | 42.55% |
| 2019 Q1 | 6.84 Billion KRW | 58.8% |
| 2019 Q3 | 7.11 Billion KRW | 21.32% |
| 2019 Q4 | 7.63 Billion KRW | 7.31% |
| 2019 FY | 57.39 Billion KRW | 266.73% |
| 2019 Q2 | 5.86 Billion KRW | -14.32% |
| 2018 Q2 | 4.15 Billion KRW | 26.92% |
| 2018 Q4 | 4.31 Billion KRW | -58.31% |
| 2018 FY | 15.65 Billion KRW | 936.69% |
| 2018 Q1 | 3.27 Billion KRW | 192.46% |
| 2018 Q3 | 10.34 Billion KRW | 149.03% |
| 2017 Q4 | -3.53 Billion KRW | -352.71% |
| 2017 FY | -1.87 Billion KRW | -151.39% |
| 2017 Q3 | 1.4 Billion KRW | 231.71% |
| 2017 Q2 | -1.06 Billion KRW | -179.86% |
| 2017 Q1 | 1.33 Billion KRW | -15.49% |
| 2016 Q4 | 1.57 Billion KRW | 18.79% |
| 2016 Q1 | 158.33 Million KRW | -97.39% |
| 2016 FY | 3.64 Billion KRW | -41.49% |
| 2016 Q2 | 579.85 Million KRW | 266.22% |
| 2016 Q3 | 1.32 Billion KRW | 128.75% |
| 2015 Q3 | 857.95 Million KRW | 801.6% |
| 2015 Q1 | -792.95 Million KRW | 0.0% |
| 2015 FY | 6.22 Billion KRW | -39.69% |
| 2015 Q2 | 95.15 Million KRW | 112.0% |
| 2015 Q4 | 6.06 Billion KRW | 606.46% |
| 2014 FY | 10.31 Billion KRW | 38.23% |
| 2014 Q3 | 1.44 Billion KRW | -51.96% |
| 2014 Q2 | 3.01 Billion KRW | 17.01% |
| 2014 Q4 | - KRW | -100.0% |
| 2014 Q1 | 2.57 Billion KRW | -12.25% |
| 2013 Q1 | 898.83 Million KRW | 143.31% |
| 2013 FY | 7.46 Billion KRW | -13.21% |
| 2013 Q2 | 1.24 Billion KRW | 38.43% |
| 2013 Q3 | 2.38 Billion KRW | 91.79% |
| 2013 Q4 | 2.93 Billion KRW | 22.9% |
| 2012 Q4 | -2.07 Billion KRW | -180.61% |
| 2012 Q1 | 3.72 Billion KRW | 0.0% |
| 2012 Q2 | 4.75 Billion KRW | 27.61% |
| 2012 Q3 | 2.57 Billion KRW | -45.88% |
| 2012 FY | 8.59 Billion KRW | -59.47% |
| 2011 FY | 21.21 Billion KRW | -20.88% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 4.63 Billion KRW | -34.89% |
| 2011 Q2 | 7.11 Billion KRW | -4.55% |
| 2011 Q1 | 7.45 Billion KRW | 116.84% |
| 2010 Q1 | 3.94 Billion KRW | -30.79% |
| 2010 FY | 26.8 Billion KRW | 38.16% |
| 2010 Q2 | 10.96 Billion KRW | 178.11% |
| 2010 Q3 | 8.43 Billion KRW | -23.04% |
| 2010 Q4 | 3.43 Billion KRW | -59.28% |
| 2009 Q1 | 3.28 Billion KRW | -43.24% |
| 2009 Q3 | 5.12 Billion KRW | -2.28% |
| 2009 Q2 | 5.24 Billion KRW | 59.73% |
| 2009 Q4 | 5.69 Billion KRW | 11.07% |
| 2009 FY | 19.4 Billion KRW | -22.57% |
| 2008 Q2 | 8.46 Billion KRW | 76.8% |
| 2008 Q3 | 6.01 Billion KRW | -28.95% |
| 2008 Q4 | 5.78 Billion KRW | -3.76% |
| 2008 FY | 25.06 Billion KRW | -18.9% |
| 2008 Q1 | 4.78 Billion KRW | -41.05% |
| 2007 Q4 | 8.12 Billion KRW | 7.72% |
| 2007 Q3 | 7.54 Billion KRW | -8.51% |
| 2007 Q2 | 8.24 Billion KRW | 17.96% |
| 2007 Q1 | 6.98 Billion KRW | 0.0% |
| 2007 FY | 30.9 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -3350.631% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 83.639% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 115.81% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 732.374% |
| Yuhan Corporation | 74.56 Billion KRW | 83.13% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -12.527% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 169.718% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 94.407% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -311.603% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 12.345% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -2009.117% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -1205.176% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 53.466% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -3350.631% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 262.181% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -211.849% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 117.983% |
| JW Holdings Corporation | 143.66 Billion KRW | 91.244% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 123.548% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 94.899% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 87.459% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 126.542% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -81.593% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -94.387% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -44.065% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -3350.631% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 74.207% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 90.571% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 87.459% |
| Yuhan Corporation | 74.56 Billion KRW | 83.13% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 39.872% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -303.505% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 70.743% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 87.459% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 38.593% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 77.108% |
| CKD Bio Corp. | -20.15 Billion KRW | 162.418% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 60.975% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 50.285% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 61.326% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 126.542% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 62.051% |
| Boryung Corporation | 68.26 Billion KRW | 81.574% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 133.546% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 12.345% |
| JW Lifescience Corporation | 32.09 Billion KRW | 60.803% |